Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus

Vaccine

Volumn 20, Issue 11-12, 2002, Pages 1497-1504

  Phillpotts, R J ^a   Jones, L D ^b   Howard, S C ^b  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^b CENTRE FOR ECOLOGY AND HYDROLOGY   (United Kingdom)

Author keywords

Immunotherapy; Monoclonal antibody; Venezuelan equine encephalitis virus

Indexed keywords

MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENCEPHALOMYELITIS; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIROGENESIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; HUMANS; LABORATORY PERSONNEL; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; OCCUPATIONAL DISEASES; ZOONOSES;

EID: 0037154855     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00505-9     Document Type: Article

References (37)

1. Epidemic Venezuelan encephalitis in La Guajira, Colombia, 1995
2. Attenuation of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea pig heart cells
3. Venezuelan equine encephalitis
4. TC83 Venezuelan encephalitis exposure during pregnancy
5. Effecto teratogenico del virus de la encefalitis equina Venezolana, una revision del problema
6. A 15 year review (1976-1990) of the safety and immunigenicity of VEE live, attenuated TC-83 and formalin-inactivated, C-84 vaccines
7. Laboratory safety for arborviruses and certain other viruses of vertebrates
8. Inactivated with Venezuelan equine encephalomyelitis vaccine prepared from attenuated (TC-83 strain) virus
9. Protective efficacies of live-attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters
10. Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in Balb/c but not C3H/HeN mice
11. TC-83 vaccine protects against disease produced by airborne or subcutaneous infection with heterologous mouse-virulent strains of Venezuelan equine encephalitis virus
12. An immunological profile of Balb/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine
13. Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine
14. Immunity to airborne challenge with Venezuelan equine encephalitis virus develops rapidly after immunisation with the attenuated vaccine strain TC-83
15. The alphaviruses: Gene expression, replication and evolution
16. The full length sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83
17. A simple device for exposure of animals to infectious micro-organisms by the airborne route
18. Humane endpoints are an objective measure of morbidity in Venezuelan encephalomyelitis virus infection of mice
19. 3,3′,5,5′-tetramethylbenzidine as an Ames test negative chromogen for horseradish peroxidase in enzyme immunoassay
20. The neutralisation site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes
21. The systemic pathology of Venezuelan equine encephalitis virus infection in humans
22. Summary of antibody workshop: The role of humoral immunity in the treatment and prevention of emerging and extant infectious diseases
23. Intranasal antibody prophylaxis for protection against viral disease
24. Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases
25. Virus persistence in vivo through selection of neutralising antibody-escape variants
26. Antigenic analysis of the surface glycoproteins of a Venezuelan equine encephalomyelitis virus (TC-83) using monoclonal antibodies
27. Variants of Venezuelan equine encephalitis virus that resist neutralization define a domain of the E2 glycoprotein
28. Synergistic interactions of antibodies in rate of virus neutralization
29. Role of complement and the Fc portion of immunoglobin G in immunity Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies
30. Antibody-mediated clearance of alphavirus infection from neurons
31. Pathogenesis of Venezuelan equine encephalitis virus infection in mice and hamsters
32. Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse
33. Venezuelan equine encephalitis in BALB/c mice. Kinetic analysis of central nervous system infection following aerosol or subcutaneous inoculation
34. Venezuelan equine encephalitis virus propogation in the olfactory tract of normal and immunised mice
35. Spread of Venezuelan equine encephalitis virus in mice olfactory tract
36. Production of humanised monoclonal antibodies for in vivo imaging and therapy